Navigation Links
Ondine Biopharma Announces Sinuwave Technologies Spinout

Ondine Biopharma Corporation, a medical technology company developing photodisinfection based products, today announced its intention to establish a wholly owned subsidiary, “Sinuwave Technologies Corporation”, dedicated to the development and commercialization of photodisinfection based products that address the chronic sinusitis market. The subsidiary will license technology developed by Ondine Biopharma over the past ten years and will leverage product development and clinical and regulatory experiences of the Ondine Biopharma and Advanced Photodynamic Therapy teams.

(Vocus) June 30, 2010 -- Ondine Biopharma Corporation (the "Company" or "Ondine") (TSX:OBP)(AIM:OBP) a medical technology company developing photodisinfection based products, today announced its intention to establish a wholly owned subsidiary, "Sinuwave Technologies Corporation", dedicated to the development and commercialization of photodisinfection based products that address the chronic sinusitis market. The subsidiary will license all relevant Ondine intellectual property and know-how for this application, including technology internally developed over the past ten years and technology obtained in Ondine's December 2009 acquisition of Advanced Photodynamic Technologies Inc. ("APT"). Sinuwave Technologies will leverage the product development, clinical and regulatory experiences of both the Ondine and APT teams.

"We believe the powerful antimicrobial and anti-inflammatory benefits of Ondine's photodisinfection technology have the potential to provide substantial relief to persons who suffer from chronic sinusitis," says Carolyn Cross, Chairman & CEO of Ondine Biopharma Corporation. "Over 43 million people in North America suffer from sinusitis. There are over 450,000 patients for whom sinus surgeries and antibiotics have been unsuccessful. We believe that we can apply our expertise as global leaders in photodisinfection to address this large unmet patient need."

About Ondine Biopharma Corporation

Ondine is developing non-antibiotic therapies for the treatment of a broad spectrum of bacterial, fungal and viral infections. The Company is focused on developing leading edge products utilizing its patented light-activated technology. Photodisinfection provides broad-spectrum antimicrobial efficacy without encouraging the formation and spread of antibiotic resistance. The Company is based in Vancouver, British Columbia, Canada, with a research and development laboratory in Bothell, Washington, USA.

For additional information, please visit and

Forward-Looking Statements:

Certain statements contained in this release containing words like "believe", "intend", "may", "expect" and other similar expressions, are forward-looking statements that involve a number of risks and uncertainties. Factors that could cause actual results to differ materially from those projected in the Company's forward-looking statements include the following: market acceptance of our technologies and products; our ability to obtain financing; our financial and technical resources relative to those of our competitors; our ability to keep up with rapid technological change; government regulation of our technologies; our ability to enforce our intellectual property rights and protect our proprietary technologies; the ability to obtain and develop partnership opportunities; the timing of commercial product launches; the ability to achieve key technical milestones in key products and other risk factors identified from time to time in the Company's public filings.

The TSX Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

For further information please contact:

Carolyn Cross
Chairman and
Chief Executive Officer
Ondine Biopharma Corporation
(604) 669-0555

Canaccord Genuity Limited, Nominated Adviser
Nominated Adviser
Ryan Gaffney
+4420 7050 6500


Read the full story at

Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved  

Related medicine news :

1. Ondine Biopharma CEO Nominated for Manning Innovation Award
2. Therapure Biopharma Inc. and Akorn, Inc. Announce Strategic Supply Contract
3. Therapure Biopharma Inc. signs multi-year manufacturing agreement with LFB Biomedicaments
4. PDL BioPharma Announces Two $0.50 Dividends in 2010
5. Therapure Biopharma Inc. Commissions its Commercial-Scale Lyophilizer
6. Securities Class Action Filed by Shepherd, Finkelman, Miller & Shah, LLP on Behalf of Hemispherx Biopharma Securities Purchasers Between February 18, 2009 and November 2, 2009
7. Therapure Biopharma Inc. and YM BioSciences Inc. Announce Partnership
8. BioProcess International Launches a New and Improved Website for Biopharmaceutical Managers and Scientists
9. Seven More Biopharmaceutical Research Companies Join PhRMA
10. Microbix and Therapure Biopharma Form Partnership to Expand Water-Based Supplies to the Pharma Industry
11. Therapure Biopharma Inc. signs fill/finish contract with Kane Biotech Inc.
Post Your Comments:
Related Image:
Ondine Biopharma Announces Sinuwave Technologies Spinout
(Date:11/25/2015)... Nairobi (PRWEB) , ... November 26, 2015 , ... ... African Union Commission (AUC), European Union (EU), ANDI Pan African Centres of Excellence, ... Nations Office in Nairobi (UNON) for the opening of the 5th African Network ...
(Date:11/25/2015)... ... November 25, 2015 , ... Lakeview Health, a Jacksonville-based ... celebrate their sobriety and show through pictures what a positive difference it makes. ... Thanksgiving with the hashtag #FacesOfGratitude on their Facebook, Twitter, and Instagram accounts. ...
(Date:11/25/2015)... Crystal Lake, IL (PRWEB) , ... November 25, 2015 , ... ... pleased to announce a recent successful appellate decision obtained by Attorneys Francisco J. Botto ... the case Adcock v. Illinois Workers’ Compensation Comm’n, 2015 IL App (2d) 130884WC. , ...
(Date:11/25/2015)... ... , ... Beddit® has launched a new Android app for use ... a more intuitive SleepScore™ that rates sleep quality on a 100-point scale and makes ... by a proprietary algorithm. Beddit analyzes the data to provide an easy to understand ...
(Date:11/25/2015)... ... November 25, 2015 , ... Today, Mothers Against Drunk Driving ... dropped below 10,000 for the first time since 2011. In 2014, there were 9,967 ... data released by the National Highway Traffic Safety Administration (NHTSA), 32,675 people were killed ...
Breaking Medicine News(10 mins):
(Date:11/24/2015)... BOULDER, Colo. , Nov. 24, 2015 /PRNewswire/ ... announced that its Chief Executive Officer, Ron ... Annual Healthcare Conference in New York.  The public ... a webcast on the Array BioPharma website.Event:Piper Jaffray ... OfficerDate:  , Wednesday, December 2, 2015Time:1:30 p.m. Eastern ...
(Date:11/24/2015)... New York , 24. November 2015 ... des Avery Breathing Pacemaker Systems, ist erfreut, ... als Clinical Consultant bekannt geben zu können. ...   --> Foto ... Stockholm (Schweden). Von 1984-1986 war ...
(Date:11/24/2015)... 24, 2015 Avery Biomedical Devices (ABD), manufacturer ... announce the appointment of Anders Jonzon , MD; ... Dr. Jonzon is a Physiologist ... Hospital, Uppsala University, Uppsala and Children,s Hospital, Karolinska, ... a fellow at the Cardiovascular Institute (UCSF). His research ...
Breaking Medicine Technology: